Vaderis leadership

Azmi Nabulsi, MD, MPH

President & CEO

Dr. Azmi Nabulsi is President & Chief Executive Officer of Vaderis Therapeutics, where he leads the advancement of a novel therapeutic program for hereditary hemorrhagic telangiectasia (HHT). A physician-scientist and biopharmaceutical executive, he brings more than 30 years of experience building and advancing medicines from discovery through regulatory approval and commercialization, with deep expertise in strategy, execution, and capital formation.

Prior to Vaderis, Azmi was a co-founder of Phathom Pharmaceuticals, where he played a central role in corporate strategy and financing, helping guide the company from inception through private financings and its evolution into a publicly traded, commercial-stage organization following FDA approval of its lead therapy. He continues to advise Phathom as a strategic consultant.

Earlier in his career, Azmi held senior global R&D leadership roles at Abbott and Takeda, where he advanced multiple clinical programs and helped shape enterprise-wide development strategies. His roles included Head of Immunology and Oncology Ventures at Abbott and Deputy Chief Medical & Scientific Officer and Head of Global
Development at Takeda.

Azmi earned his MD from Ain Shams University in Cairo and his MPH from the University of Minnesota. He also serves as a board member and scientific advisor to multiple biotechnology companies.